Drug Database · Clinicians

Atorvastatin + Fenofibrate

Brands (4) Fenostat, Atorfibrate, Atorsam-F…Show all

Lipid modifying agent (HMG-CoA reductase Inhibitor/Fibrate); HMG-CoA reductase inhibitor/ lipid modifying agent; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug7 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated US FDA label

    Kidney dosing: Atorvastatin (single-agent)
    Show full dosing details
    eGFR ≥60
    No adjustment (label).
    eGFR 30–59
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    eGFR 15–29
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    eGFR <15 (not on dialysis)
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    Hemodialysis (intermittent)
    No dose adjustment (not dialyzed; label). KDIGO: do not start a statin in most patients already on dialysis; continue if already taking one at dialysis initiation.
    Peritoneal dialysis
    No label adjustment; no PD data.
    CRRT
    No data in label.
    • Dialyzable? Not expected to be significantly removed by hemodialysis (label).
    • Monitoring Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label).

    From the Atorvastatin monograph (renalcarematters.com, reviewed).

  • Use: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia… US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 10 mg/160 mg, 20 mg/160 mg, 160 mg/10 mg

Registered products in the Philippines

7 products registered with the Food and Drug Administration (FDA) Philippines list Atorvastatin + Fenofibrate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products7
Philippine FDA-registered products for Atorvastatin + Fenofibrate
Package insert
AtorfibrateAtorvastatin (as calcium) + Fenofibrate
10mg/160mg Film-coated TabletAlu / Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Samson Laboratories Pvt. Ltd.India
A. Pendragon International Distribution OpcImporter: Khriz Pharma Trading Inc.
DRP-13177-01
Dec 14, 2027
Atorsam-FAtorvastatin (As Calcium) + Fenofibrate
10mg/160mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Samson Laboratories Pvt. Ltd.India
Khriz Pharma Trading Inc.
DRP-13177
Dec 14, 2027
FenostatAtorvastatin (as calcium) + Fenofibrate
10 mg/160 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY48064
Feb 9, 2031
FenostatAtorvastatin (as calcium) + Fenofibrate
10mg/160mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Ajanta Pharma Ltd.India
Ajanta Pharma Philippines, Inc.
DR-XY39060
Feb 21, 2029
FenostatAtorvastatin (as calcium) + Fenofibrate
20 mg/160 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma Ltd.India
Ajanta Pharma Philippines, Inc.
DR-XY44324
Feb 9, 2031
FenostatAtorvastatin (as calcium) + Fenofibrate
20 mg/160 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY48063
Feb 11, 2031
FibrovasFenofibrate + Atorvastatin (as calcium)
160 mg/10 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc
DR-XY46755
Oct 24, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .